Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.52 |
| ▸ | CCNC | P24863 | 3/20 | 0.46 |
| ▸ | CDK8 | P49336 | 3/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 4/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 4/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19902605 | 0.89 | CCNC (0.55) | CCNCCDK8ROCK1AURKAAURKB | |
| SCHEMBL17452936 | 0.89 | ROCK2 (0.57) | USP30CCNCCDK8ROCK1AURKA | |
| SCHEMBL19902593 | 0.84 | USP30 (0.54) | USP30CCNCCDK8ROCK1AURKA | |
| SCHEMBL19902716 | 0.83 | USP30 (0.51) | USP30CCNCCDK8ROCK1AURKA | |
| SCHEMBL19902646 | 0.83 | USP30 (0.55) | USP30CCNCCDK8ROCK1AURKA | |
| SCHEMBL19902513 | 0.81 | GSK3B (0.46) | USP30CCNCCDK8ROCK1ROCK2 | |
| SCHEMBL19902710 | 0.80 | GPR183 (0.44) | ROCK2HPGDSGSK3B | |
| SCHEMBL19902490 | 0.80 | HPGDS (0.48) | USP30ROCK1ROCK2HPGDS | |
| SCHEMBL19902655 | 0.79 | USP30 (0.56) | USP30CCNCCDK8ROCK1ROCK2 | |
| SCHEMBL19902362 | 0.78 | ROCK2 (0.42) | ROCK1ROCK2HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2018-06-07 | — | — | US | disclosed |
| US-9902702-B2 | Spirocycloheptanes as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | ROCK1, MYLK, ROCK2 | USP30 3527/4885CCNC 1995/4885CDK8 1196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.